ClinicalTrials.gg
RecruitingNCT07667803EmboldUpdated Oct 13, 2026

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

A Phase 3 interventional study of Elecoglipron and Placebo in Weight Management, sponsored by AstraZeneca. Recruiting at 325 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 13, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

Read the detailed description

This is a Phase III, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of 2 doses of elecoglipron compared with placebo, given once daily as oral tablets. This protocol covers two independent pivotal studies in adults aged 18 years and above, who are living with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 25 kg/m2) and have at least 1 weight-related comorbidity (Hypertension, Prediabetes, Dyslipidemia, CV disease and/or Obstructive sleep apnea) without T2DM (Study 1) and as well as those who are living with obesity or overweight with T2DM (Study 2). Approximately 3000 participants will be randomized in the study 1 and 1500 participants in the study 2. The primary endpoint is percent change in body weight from baseline at 72 weeks.

02

Conditions studied

  • Weight Management
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Legal age of consent and at least 18 years old
  • Study 1 -

    • ≥ 30 kg/m2 or
    • 25 kg/m2 ≤ BMI \< 30 kg/m2 with at least one of the following weight-related comorbidities:
    • Hypertension
    • Prediabetes
    • Dyslipidemia
    • Cardiovascular disease
    • Obstructive sleep apnea.
  • Study 2 - BMI ≥ 25 kg/m2 and T2DM defined as below:

    • Established diagnosis of T2DM
    • Without established diagnosis of T2DM and ≥ 6.5% (48 mmol/mol) at the screening visit
  • Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion criteria

Exclusion Criteria

  • Study 1 - Established diagnosis of T1DM or T2DM.
  • Study 2 - Any of the following medical history, laboratory values, or complications related to diabetes:

    • T1DM
    • ≥ 10% (86 mmol/mol) at the screening visit
    • Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema.
    • Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
  • History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis
  • History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
4,500 participants (estimated)

Study arms

  • Experimental
    Arm 1 - Dose 1

    Active IMP

    Drug: Elecoglipron

  • Experimental
    Arm 2 - Dose 2

    Active IMP

    Drug: Elecoglipron

  • Placebo comparator
    Arm 3 - Placebo

    Placebo matching elecoglipron

    Drug: Placebo

Interventions

  • Elecoglipron film-coated tablet once daily

    Also known as: Active IMP

  • DrugPlacebo

    Placebo matching elecoglipron film-coated tablet once daily

06

What researchers measure

Primary outcomes

  1. Percent body weight loss

    Percent change from baseline to Week 72 in body weight

    Time frame: 72 weeks

Secondary outcomes

  1. Absolute body weight loss

    Absolute change from baseline to Week 72 in body weight (kg)

    Time frame: 72 weeks

  2. Total body weight loss of at least 5%, 10%, and 15%

    * Achieved ≥ 5% body weight loss from baseline at Week 72 * Achieved ≥ 10% body weight loss from baseline at Week 72 * Achieved ≥ 15% body weight loss from baseline at Week 72

    Time frame: 72 weeks

  3. Percent body weight loss in participants with body mass index (BMI) ≥ 27 kg/m2 at baseline

    Percent change from baseline to Week 72 in body weight

    Time frame: 72 weeks

  4. Waist circumference reduction

    Absolute change from baseline to Week 72 in waist circumference (cm)

    Time frame: 72 weeks

  5. Glycemic control

    Change from baseline to Week 72 in hemoglobin A1c (HbA1c) (%)

    Time frame: 72 weeks

  6. Achieving normoglycemia in participants with HbA1c ≥ 5.7% (39 mmol/mol) at baseline

    Achieved normoglycemia (HbA1c \< 5.7% \[39 mmol/mol\]) at Week 72

    Time frame: 72 weeks

  7. Study 2 only: Achieving glycemic control in participants with HbA1c ≥ 7.0% (53 mmol/mol) at baseline

    * Achieved HbA1c \< 7.0% (53 mmol/mol) at Week 72 * Achieved HbA1c ≤ 6.5% (48 mmol/mol) at Week 72

    Time frame: 72 weeks

  8. Systolic blood pressure reduction

    Change from baseline to Week 72 in systolic blood pressure (mmHg)

    Time frame: 72 weeks

07

Study locations

220 of 325 sites recruiting
  • Research Site
    Birmingham, Alabama 35205, United States
    Recruiting
  • Research Site
    Dothan, Alabama 36305, United States
    Recruiting
  • Research Site
    Chandler, Arizona 85225, United States
    Recruiting
  • Research Site
    Sun City, Arizona 85373, United States
    Not yet recruiting
  • Research Site
    Little Rock, Arkansas 72205, United States
    Recruiting
  • Research Site
    Lynwood, California 90262, United States
    Recruiting
  • Research Site
    Rolling Hills Estates, California 90274, United States
    Recruiting
  • Research Site
    Sacramento, California 95821, United States
    Recruiting
  • Research Site
    Arvada, Colorado 80002, United States
    Recruiting
  • Research Site
    New Haven, Connecticut 06519, United States
    Not yet recruiting
  • Research Site
    Plantation, Florida 33324, United States
    Not yet recruiting
  • Research Site
    Tampa, Florida 33606, United States
    Recruiting
  • Research Site
    Woodstock, Georgia 30189, United States
    Recruiting
  • Research Site
    Ammon, Idaho 83406, United States
    Recruiting
  • Research Site
    Melrose Park, Illinois 60160, United States
    Recruiting
  • Research Site
    Indianapolis, Indiana 46254, United States
    Recruiting
  • Research Site
    Wichita, Kansas 67218, United States
    Recruiting
  • Research Site
    Louisville, Kentucky 40213, United States
    Recruiting
  • Research Site
    Alexandria, Louisiana 71303, United States
    Recruiting
  • Research Site
    Baltimore, Maryland 21229, United States
    Not yet recruiting
  • Research Site
    Potomac, Maryland 20854, United States
    Recruiting
  • Research Site
    White Marsh, Maryland 21162, United States
    Recruiting
  • Research Site
    Ypsilanti, Michigan 48197, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Ridgeland, Mississippi 39157, United States
    Recruiting
  • Research Site
    Kansas City, Missouri 64114, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63123, United States
    Recruiting
  • Research Site
    Reno, Nevada 89511, United States
    Not yet recruiting
  • Research Site
    Albuquerque, New Mexico 87106, United States
    Recruiting
  • Research Site
    Albany, New York 12205, United States
    Not yet recruiting
  • Research Site
    Laurelton, New York 11413, United States
    Recruiting
  • Research Site
    Long Island City, New York 11106, United States
    Recruiting
  • Research Site
    Greensboro, North Carolina 27408, United States
    Recruiting
  • Research Site
    Raleigh, North Carolina 27609, United States
    Recruiting
  • Research Site
    Rocky Mount, North Carolina 27804, United States
    Recruiting
  • Research Site
    Statesville, North Carolina 28625, United States
    Recruiting
  • Research Site
    Columbus, Ohio 43228, United States
    Recruiting
  • Research Site
    Dayton, Ohio 45424, United States
    Recruiting
  • Research Site
    Oklahoma City, Oklahoma 73134, United States
    Recruiting
  • Research Site
    Tulsa, Oklahoma 74133, United States
    Recruiting
  • Research Site
    Portland, Oregon 97223, United States
    Not yet recruiting
  • Research Site
    DuBois, Pennsylvania 15801, United States
    Recruiting
  • Research Site
    Newport, Pennsylvania 17074, United States
    Recruiting
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
    Not yet recruiting
  • Research Site
    East Providence, Rhode Island 02914, United States
    Not yet recruiting
  • Research Site
    Charleston, South Carolina 29407, United States
    Recruiting
  • Research Site
    Gaffney, South Carolina 29340, United States
    Recruiting
  • Research Site
    Rapid City, South Dakota 57701, United States
    Not yet recruiting
  • Research Site
    Franklin, Tennessee 37067, United States
    Recruiting
  • Research Site
    Knoxville, Tennessee 37912, United States
    Recruiting
  • Research Site
    Dallas, Texas 75254, United States
    Recruiting
  • Research Site
    Houston, Texas 77081, United States
    Recruiting
  • Research Site
    Humble, Texas 77346, United States
    Recruiting
  • Research Site
    Irving, Texas 75063, United States
    Recruiting
  • Research Site
    Sandy City, Utah 84070, United States
    Not yet recruiting
  • Research Site
    Midlothian, Virginia 23112, United States
    Recruiting
  • Research Site
    Morgantown, West Virginia 26501, United States
    Recruiting
  • Research Site
    Buenos Aires, C1120AAC, Argentina
    Recruiting
  • Research Site
    Buenos Aires, C1425AGC, Argentina
    Recruiting
  • Research Site
    CABA, 1056, Argentina
    Recruiting
  • Research Site
    CABA, C1061, Argentina
    Recruiting
  • Research Site
    Caba, C1128AAF, Argentina
    Recruiting
  • Research Site
    Capital Federal, C1014A, Argentina
    Recruiting
  • Research Site
    Granadero Baigorria, S2152BOF, Argentina
    Recruiting
  • Research Site
    Lanus, B1824KAJ, Argentina
    Recruiting
  • Research Site
    Rosario, 2000, Argentina
    Recruiting
  • Research Site
    Rosario, S2000CVD, Argentina
    Recruiting
  • Research Site
    San Nicolás, B2900DMH, Argentina
    Recruiting
  • Research Site
    San Vicente, 5006, Argentina
    Not yet recruiting
  • Research Site
    Botany, 2019, Australia
    Recruiting
  • Research Site
    Camberwell, 3124, Australia
    Recruiting
  • Research Site
    Charlestown, 2290, Australia
    Recruiting
  • Research Site
    Maroubra, 2035, Australia
    Recruiting
  • Research Site
    St Albans, 3021, Australia
    Recruiting
  • Research Site
    St Leonards, 2065, Australia
    Recruiting
  • Research Site
    Belém, 66073-005, Brazil
    Not yet recruiting
  • Research Site
    Brasília, 72145-450, Brazil
    Not yet recruiting
  • Research Site
    Campinas, 13060-080, Brazil
    Not yet recruiting
  • Research Site
    Campinas, 13092133, Brazil
    Not yet recruiting
  • Research Site
    Curitiba, 80040-110, Brazil
    Recruiting
  • Research Site
    Fortaleza, 60426-000, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 90430-001, Brazil
    Not yet recruiting
  • Research Site
    São José dos Campos, 12230-001, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 01228-000, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 01236-030, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 04012-180, Brazil
    Not yet recruiting
  • Research Site
    Calgary, Alberta T2V 4J2, Canada
    Recruiting
  • Research Site
    Calgary, Alberta T3R 1W9, Canada
    Recruiting
  • Research Site
    Vancouver, British Columbia V5Y 3W2, Canada
    Recruiting
  • Research Site
    Victoria, British Columbia V8V 4A1, Canada
    Recruiting
  • Research Site
    Moncton, New Brunswick E1G 1A7, Canada
    Recruiting
  • Research Site
    Truro, Nova Scotia B2N 1L2, Canada
    Recruiting
  • Research Site
    Brampton, Ontario L6T 0G1, Canada
    Recruiting
  • Research Site
    Hamilton, Ontario L8L 5G8, Canada
    Recruiting
  • Research Site
    Niagara Falls, Ontario L2H 1H5, Canada
    Recruiting
  • Research Site
    North York, Ontario M6B 3H7, Canada
    Recruiting
  • Research Site
    Sarnia, Ontario N7T 4X3, Canada
    Recruiting
  • Research Site
    Scarborough Village, Ontario M1R 0B1, Canada
    Recruiting
  • Research Site
    Stouffville, Ontario L4A1H2, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M3J 0K2, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M6G 1M2, Canada
    Recruiting

Showing the first 100 of 325 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jul 2028, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2026
First posted
Jun 25, 2026
StartActual
Jun 29, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 30, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
106 sites changed recruiting status (106 now recruiting)
Show 106 sites
  • Research Site · Birmingham, United StatesNot yet recruiting→Recruiting
  • Research Site · Rolling Hills Estates, United StatesNot yet recruiting→Recruiting
  • Research Site · Melrose Park, United StatesNot yet recruiting→Recruiting
  • Research Site · Indianapolis, United StatesNot yet recruiting→Recruiting
  • Research Site · Wichita, United StatesNot yet recruiting→Recruiting
  • Research Site · Ridgeland, United StatesNot yet recruiting→Recruiting
  • Research Site · St Louis, United StatesNot yet recruiting→Recruiting
  • Research Site · Albuquerque, United StatesNot yet recruiting→Recruiting
  • Research Site · Rocky Mount, United StatesNot yet recruiting→Recruiting
  • Research Site · Oklahoma City, United StatesNot yet recruiting→Recruiting
  • Research Site · Newport, United StatesNot yet recruiting→Recruiting
  • Research Site · Franklin, United StatesNot yet recruiting→Recruiting
  • Research Site · Knoxville, United StatesNot yet recruiting→Recruiting
  • Research Site · Houston, United StatesNot yet recruiting→Recruiting
  • Research Site · Humble, United StatesNot yet recruiting→Recruiting
  • Research Site · Midlothian, United StatesNot yet recruiting→Recruiting
  • Research Site · Morgantown, United StatesNot yet recruiting→Recruiting
  • Research Site · CABA, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Granadero Baigorria, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Lanus, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Rosario, ArgentinaNot yet recruiting→Recruiting
  • Research Site · San Nicolás, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Curitiba, BrazilNot yet recruiting→Recruiting
  • Research Site · Calgary, CanadaNot yet recruiting→Recruiting
  • Research Site · Binzhou, ChinaNot yet recruiting→Recruiting
  • Research Site · Chengdu, ChinaNot yet recruiting→Recruiting
  • Research Site · Deyang, ChinaNot yet recruiting→Recruiting
  • Research Site · Ganzhou, ChinaNot yet recruiting→Recruiting
  • Research Site · Guangzhou, ChinaNot yet recruiting→Recruiting
  • Research Site · Haikou, ChinaNot yet recruiting→Recruiting
  • …and 76 more on the registry record
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    111 sites changed recruiting status (111 now recruiting)
    Show 111 sites
    • Research Site · Birmingham, United StatesNot yet recruiting→Recruiting
    • Research Site · Rolling Hills Estates, United StatesNot yet recruiting→Recruiting
    • Research Site · Melrose Park, United StatesNot yet recruiting→Recruiting
    • Research Site · Indianapolis, United StatesNot yet recruiting→Recruiting
    • Research Site · Wichita, United StatesNot yet recruiting→Recruiting
    • Research Site · Ridgeland, United StatesNot yet recruiting→Recruiting
    • Research Site · St Louis, United StatesNot yet recruiting→Recruiting
    • Research Site · Albuquerque, United StatesNot yet recruiting→Recruiting
    • Research Site · Rocky Mount, United StatesNot yet recruiting→Recruiting
    • Research Site · Oklahoma City, United StatesNot yet recruiting→Recruiting
    • Research Site · Newport, United StatesNot yet recruiting→Recruiting
    • Research Site · Franklin, United StatesNot yet recruiting→Recruiting
    • Research Site · Knoxville, United StatesNot yet recruiting→Recruiting
    • Research Site · Houston, United StatesNot yet recruiting→Recruiting
    • Research Site · Humble, United StatesNot yet recruiting→Recruiting
    • Research Site · Midlothian, United StatesNot yet recruiting→Recruiting
    • Research Site · Morgantown, United StatesNot yet recruiting→Recruiting
    • Research Site · CABA, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Granadero Baigorria, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Lanus, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Rosario, ArgentinaNot yet recruiting→Recruiting
    • Research Site · San Nicolás, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Curitiba, BrazilNot yet recruiting→Recruiting
    • Research Site · Calgary, CanadaNot yet recruiting→Recruiting
    • Research Site · Binzhou, ChinaNot yet recruiting→Recruiting
    • Research Site · Chengdu, ChinaNot yet recruiting→Recruiting
    • Research Site · Chengdu, ChinaNot yet recruiting→Recruiting
    • Research Site · Deyang, ChinaNot yet recruiting→Recruiting
    • Research Site · Ganzhou, ChinaNot yet recruiting→Recruiting
    • Research Site · Guangzhou, ChinaNot yet recruiting→Recruiting
    • …and 81 more on the registry record
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07667803
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jun 29, 2026
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
Prof. Melanie Davies, MBChB
principal investigator · Diabetes Research Centre Leicester Diabetes Centre - Bloom University of Leicester
Dr. Ania Jastreboff, MD, PhD
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion